SciELO - Scientific Electronic Library Online

 
vol.32 número5Estudo CUMPRO: CUMPrimento do Rastreio Oncológico em profissionais de um AceSO descortinar de uma epigastralgia índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Portuguesa de Medicina Geral e Familiar

versão impressa ISSN 2182-5173

Resumo

MENDES, Paula  e  CARDOSO, Vítor Portela. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers: evidence for their effects on mortality and major cardiovascular events in hypertensive diabetics. Rev Port Med Geral Fam [online]. 2016, vol.32, n.5, pp.330-338. ISSN 2182-5173.

Objective: Our aim was to assess the evidence for the effects of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) on mortality and major cardiovascular events in individuals with hypertension and diabetes. Data Sources: National Guideline Clearinghouse, Guidelines Finder, Canadian Medical Association Practice Guidelines, Cochrane Library, DARE, Bandolier, MEDLINE, Index of Portuguese Medical Journals and General Directorate of Health databases. Methods: The two authors independently performed a search of meta-analyzes (MA), systematic reviews (SR), randomized clinical trials (RCT) and clinical practice guidelines (CPG), published between 31/08/2009 and 31/08/2014 in Portuguese, Spanish, English and French languages. We used the MeSH terms: Diabetes Mellitus AND Hypertension AND Angiotensin-Converting Enzyme Inhibitors OR Angiotensin Receptor Antagonists. The strength of recommendation taxonomy scale was used for the allocation of levels of evidence (LE) and strength of recommendation (SR). Results: Of the 478 articles found, we included five MA and sixCPG in this report. A Cochrane MA showed that ACE inhibitors significantly decreased mortality from all causes (LE 1) and one MA concluded that this class of medications decreased the risk of myocardial infarction (LE 1). The use of ARB was shown to decrease the risk of stroke in one MA. Another MA showed no significant differences between the two classes of drugs. A recent MA found that ACE inhibitors significantly decreased all-cause mortality, cardiovascular mortality, myocardial infarction, and heart failure (LE 1). In the same MA, ARB decreased the risk of heart failure. Most guidelines recommend ACE inhibitors or ARBs as first line therapy for hypertension in diabetic patients. Conclusions: The effects of ACE inhibitors and ARB on mortality and cardiovascular events appear to be different. We found consistent evidence favoring the use of ACE inhibitors as a first option in preventing morbidity and mortality in this population (SR A)

Palavras-chave : Diabetes mellitus; Hypertension; Inhibitors of angiotensin converting enzyme; Angiotensin receptor antagonists.

        · resumo em Português     · texto em Português     · Português ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons